Purpose: Drug-induced uveitis is a well-known effect of ocular inflammation that has been reported with many medications. Pembrolizumab is a newer generation of the anti-programmed cell death-1 monoclonal antibodies that was recently approved by the Food and Drug Administration for the treatment of advanced melanoma. Immune-mediated adverse events involving different organs have been reported in recent literature in association with this drug. We present the first reported case of uveitis in association with pembrolizumab therapy.
Case Report: An 82-year-old man with stage IV melanoma was started on pembrolizumab infusion treatment every 3 weeks. Two months after initiating therapy, he presented with bilateral severe anterior uveitis and papillitis with fast and complete recovery after withholding further pembrolizumab infusions and treatment with topical steroid. Uveitis recurred after restarting pembrolizumab therapy.
Conclusions: In current clinical practice, many new drugs are being approved, requiring better characterization of the prevalence, onset, and nature of adverse events in order to aid development of effective management strategies. Ophthalmologists should keep in mind that drugs are always a possible cause of ocular inflammation in patients presenting with uveitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/ejo.5000724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute intra ocular inflammation following intravitreal injections of faricimab: A multicentric case series.
Eur J Ophthalmol
December 2024
Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, University Paris Est Créteil, Créteil, France.
Purpose: To report 8 cases of acute intra ocular inflammation (IOI) following intravitreal injections (IVI) of faricimab in patients with age related macular degeneration (AMD), retinal vein occlusion (RVO) and macular neovascularization associated with chronic central serous retinopathy (CSR).
Methods: This is a multicentric retrospective observational case-series. Cases of acute IOI that occurred in 5 different institutions in France and Italy between November 2023 and June 2024 were reported.
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series.
BMC Ophthalmol
December 2024
Vista Augenklinik Binningen, Hauptstrasse 55, Binningen, 4102, Switzerland.
Background: Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting such cases in clinical practice helps evaluate potential risk of these agents.
Case Presentation: In this case series, a cluster of 8 patients manifesting acute intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injection at three different centers are described.
Ocular Syphilis With Unilateral Optic Papillitis and Outer Retinopathy Complicated by Diabetic Retinopathy.
Cureus
October 2024
Ophthalmology, Tokyo Women's Medical University, Tokyo, JPN.
Syphilis has been increasing in adult infections in recent years, and ocular syphilis includes not only uveitis but also a variety of optic nerve and retinal lesions. We report a case of syphilis that caused unilateral optic papillitis and outer retinopathy complicated by diabetic retinopathy and improved with antibiotic treatment. The patient was a 61-year-old woman.
View Article and Find Full Text PDFA Rare Case of Rash, Blurry Vision, and Papilledema Caused by Isolated Ocular Syphilis.
Cureus
October 2024
Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, USA.
Papilledema is a high-risk cause of vision changes in the Emergency Department (ED) and a critical physical examination finding because of its close association with etiologies that may progress to vision loss or death. Syphilis is a rare infectious cause of papilledema, with scarce case reports published showing its ability to develop such sequela. We present a case of a 35-year-old male with a past medical history of newly diagnosed HIV who originally presented to the ED with a rash and rapidly worsening visional changes.
View Article and Find Full Text PDFDiagnostic and Therapeutic Insights Into Pediatric Neurosarcoidosis: Observations From French Pediatric Rheumatology Centers.
Pediatr Neurol
January 2025
Department of General Pediatrics, Pediatric Internal Medicine, Rheumatology and Infectious Diseases, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Autoimmune Diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, INSERM, Centre de Recherche sur l'inflammation UMR 1149, Paris, France. Electronic address:
Article Synopsis
- - The study reviewed 11 pediatric patients diagnosed with neurosarcoidosis (NS), predominantly affecting girls, with an average diagnosis age of around 10 to 11.5 years, highlighting typical neurological symptoms such as headaches and eye involvement.
- - Most patients experienced meningitis and were treated primarily with corticosteroids and TNF-alpha inhibitors, with eight out of 11 requiring biologic therapies to achieve remission.
- - The findings emphasize the importance of recognizing the clinical features of pediatric NS and suggest that early intervention with TNF-alpha biologics can lead to better management outcomes for these children.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!